Reviewer's report

Title: Follow-up of Phase I Trial of Adalimumab and Rosiglitazone in FSGS: III. Report of the FONT Study Group

Version: 3 Date: 22 December 2009

Reviewer: Therese Jungraithmayr

Reviewer's report:

Revisions and changes have been made carefully. Regarding the percentages of patients reaching ESRD in comparison to those with stabilisation of GFR under either medication, data are as for now not convincing as "promising" drugs for this indication. I therefore recommend, the manuscript should exclusively describe the course after treatment until time of assessment without any (positive) validation! The presented data are not proving a positive effect yet, not even a tendency. However, more conclusive data of the phase II are awaited.